Ecnoglutide

Also known as: XW003

Status

In trials. Not approved in the United States. In development with Sciwind Biosciences.

What it is

A weekly GLP-1 agonist engineered for cAMP-biased signaling, furthest along in China.

What published research measured

Engineered to bias signaling toward the cAMP pathway rather than beta-arrestin recruitment, on the theory that this improves the efficacy-to-tolerability ratio. Phase 3 trials in China have reported weight reduction in the range expected of a well-dosed GLP-1 agonist. Western regulatory data is limited, so read the trial population carefully before generalising the figures.

Source

Ji L et al. 2025 — Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentr… · He Y et al. 2025 — Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diab… · Zhu D et al. 2024 — Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-c…

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.